2Serruys PW, Degertekin M, Tanabe K, et al. Intravascular ultrasound findings in the multicenter, randomized, double-blind RAVEL (randomized study with the sirolimus-eluting velocity balloon-expandable stent in the treatment of patients with de novonative coronary artery lesions) trial. Circulation, 2002, 106 (7): 798-803.
3Sousa JE, Costa MA, Abizaid A, et al. Sirollmuseluting stent for the treatment of instent restenosis: a quantitative coronary an- giography and three-dimensional intravascular ultrasound study. Circulation, 2003, 107( 1 ) : 24-27.
4Park SJ, Shim WH, Ho DS, et al. A paclitaxel eluting stent for the prevention of coronary restenosis. N Engl J Med, 2003, 348 (16): 1537-1545.
5Perlman H, Luo Z, Krasinski K, et al. Adenovirus-mediated delivery of the gax transcription factor to rat carotid arteries in- hibits smooth muscle proliferation and induces apoptosis. C, ene Ther, 1999, 6(5): 758-763.
6Ascher E, Scheinman M, Hingorani A, et al. Effect of p53 gene. therapy combined with CTLA4Ig selective immunosuppression on prolonged neointima formation reduction in a rat model. Ann Vase Surg, 2000, 14(4): 385-392.
7Lamfers ML, Lardenoye JH, de Vries MR, et al. In vivo sup- pression of restenosis in balloon-injured rat carotid artery by adenoviras-mediated gene transfer of the cell surface-directed plasmin inhibitor ATF BPTI. Gene Ther, 2001, 8(7): 534-541.
8Ikeno F, Buehbinder M, Yeung AC. Novel stent and delivery systems for the treatment of bifurcation lesions: porcine coronary artery model. Cardiovasc Revasc Med, 2007, 8( 1 ) : 38-42.
9Schwartz RS, Edelman ER, Carter A, et al.Drug-eluting stents in preclinical studies: recommended evaluation from a consensus group. Circulation, 2002, 106(14) : 1867-1873.
